Status:

COMPLETED

A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis

Lead Sponsor:

SinoMab BioScience Ltd

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

This was an open phase I trial to evaluate the pharmacokinetic, pharmacodynamic, safety and clinical activity profiles of anti-CD22 monoclonal antibody SM03 in patients with active RA.

Detailed Description

This was an open phase I trial to evaluate the PK, PD, safety,tolerability, efficacy, and immunogenicity of SM03 in patients with RA. The total study duration was approximately 16 weeks for each parti...

Eligibility Criteria

Inclusion

  • Rheumatoid arthritis (RA) for ≥ 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis.
  • Moderate to severe active RA with swollen joint count (SJC) ≥ 6 (66 joint count), and tender joint count (TJC) ≥ 8 (68 joint count) at screening and baseline.
  • At screening, either C-reactive protein (CRP) ≥ 0.6 mg/dL (6 mg/L), or Erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour, or Morning stiffness of joint for ≥ 45 minutes.
  • Receiving methotrexate (MTX) 7.5 - 25mg/week (oral) for at least 12 weeks, at a stable dose over the past 4 weeks.

Exclusion

  • Females who are pregnant, breastfeeding, or planning a pregnancy during the Treatment Period of and 12 months after the last infusion of study drug.
  • Rheumatic autoimmune disease other than RA.
  • Use of any biological DMARDs for RA within past 6 months.
  • Active infection, or history of serious or chronic infection.
  • Any significant cardiac disease, moderate to severe chronic obstructive pulmonary disease.
  • Allergy or sensitivity to components of the drug vial or any of the materials used for infusion

Key Trial Info

Start Date :

August 14 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 16 2013

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT04704492

Start Date

August 14 2012

End Date

December 16 2013

Last Update

January 11 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clinical Pharmacology Research Center & Translational Medicine Centre, Peking Union Medical College Hospital

Beijing, China, 100032